StockData
Kiora Pharmaceuticals Inc logo

Kiora Pharmaceuticals Inc (KPRX) stock

KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.93−0.05 (-5.30%)

Close on Nov 17, 2026Market cap $4.11MP/E –Yield –

Kiora Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Kiora Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$12.83M. For fiscal 2025 it was -$12.83M, down 384.5% from the year before. The highest annual figure on record is $4.51M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.83M-384.5%
FY2024Dec 31, 2024$4.51M–
FY2023Dec 31, 2023-$12.59M–
FY2022Dec 31, 2022-$12.31M–
FY2021Dec 31, 2021-$14.24M–
FY2020Dec 31, 2020-$6.87M–
FY2018Dec 31, 2018-$10.84M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.21M–
Q1 FY2026Mar 31, 2026-$2.51M–
Q4 FY2025Dec 31, 2025-$7.31M–
Q3 FY2025Sep 30, 2025-$794.44K–
Q2 FY2025Jun 30, 2025-$2.40M–
Q1 FY2025Mar 31, 2025-$2.33M-117.6%
Q4 FY2024Dec 31, 2024-$2.56M–
Q3 FY2024Sep 30, 2024-$3.60M–
Q2 FY2024Jun 30, 2024-$2.54M–
Q1 FY2024Mar 31, 2024$13.22M–
Q4 FY2023Dec 31, 2023-$2.12M–
Q3 FY2023Sep 30, 2023-$5.92M–
Q2 FY2023Jun 30, 2023-$2.63M–
Q1 FY2023Mar 31, 2023-$1.92M–
Q4 FY2022Dec 31, 2022-$2.63M–
Q3 FY2022Sep 30, 2022-$3.70M–
Q2 FY2022Jun 30, 2022-$2.40M–
Q1 FY2022Mar 31, 2022-$3.57M–
Q4 FY2021Dec 31, 2021-$6.37M–
Q3 FY2021Sep 30, 2021-$3.04M–
Q2 FY2021Jun 30, 2021-$2.82M–
Q1 FY2021Mar 31, 2021-$2.01M–
Q4 FY2020Dec 31, 2020-$1.17M–
Q3 FY2020Sep 30, 2020-$2.01M–
Q2 FY2020Jun 30, 2020-$1.72M-307.7%
Q1 FY2020Mar 31, 2020-$1.97M–
Q3 FY2019Sep 30, 2019-$3.45M–
Q2 FY2019Jun 30, 2019-$1.87M–
Q1 FY2019Mar 31, 2019$828.64K–
Q4 FY2018Dec 31, 2018-$2.49M–
Q3 FY2018Sep 30, 2018-$3.18M–
Q2 FY2018Jun 30, 2018-$2.80M–
Q1 FY2018Mar 31, 2018-$2.38M–
Q3 FY2017Sep 30, 2017-$4.14M–
Q2 FY2017Jun 30, 2017-$3.33M–
Q1 FY2017Mar 31, 2017-$2.92M–
Q3 FY2016Sep 30, 2016-$3.38M–

More Kiora Pharmaceuticals figures

See a number that looks wrong?